Definium Therapeutics (NASDAQ:DFTX) Research Coverage Started at Wolfe Research

Wolfe Research assumed coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a research note published on Monday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $25.00 target price on the stock.

Several other equities analysts have also commented on DFTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday, January 22nd. Needham & Company LLC restated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th. Jefferies Financial Group assumed coverage on shares of Definium Therapeutics in a report on Thursday, January 29th. They issued a “buy” rating and a $30.00 price target for the company. JonesTrading assumed coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price objective on the stock. Finally, Canaccord Genuity Group upped their target price on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $34.20.

Definium Therapeutics Stock Up 1.0%

Shares of DFTX stock opened at $17.62 on Monday. The stock’s fifty day moving average price is $15.47 and its 200 day moving average price is $12.72. Definium Therapeutics has a 1-year low of $4.70 and a 1-year high of $18.70. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -8.64 and a beta of 2.57. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30.

Insider Activity at Definium Therapeutics

In other Definium Therapeutics news, insider Daniel Karlin sold 5,600 shares of the company’s stock in a transaction on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the sale, the insider directly owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Robert Barrow sold 25,791 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $339,151.65. Following the transaction, the chief executive officer owned 778,477 shares of the company’s stock, valued at $10,236,972.55. The trade was a 3.21% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 42,667 shares of company stock worth $561,071 over the last three months. Company insiders own 2.26% of the company’s stock.

Institutional Investors Weigh In On Definium Therapeutics

Several hedge funds have recently bought and sold shares of DFTX. Marshall Wace LLP grew its stake in shares of Definium Therapeutics by 31.9% during the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after purchasing an additional 828,067 shares during the period. Commodore Capital LP boosted its holdings in Definium Therapeutics by 10.5% during the second quarter. Commodore Capital LP now owns 5,000,000 shares of the company’s stock worth $32,450,000 after buying an additional 475,000 shares in the last quarter. Orbimed Advisors LLC acquired a new stake in Definium Therapeutics during the third quarter valued at $4,337,000. Rosalind Advisors Inc. increased its holdings in Definium Therapeutics by 78.6% in the third quarter. Rosalind Advisors Inc. now owns 750,000 shares of the company’s stock valued at $8,842,000 after buying an additional 330,000 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Definium Therapeutics by 424.9% in the third quarter. Two Sigma Investments LP now owns 296,443 shares of the company’s stock worth $3,495,000 after acquiring an additional 239,965 shares during the period. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.